Becker’s Spine Review is a publication for orthopedic and spine surgeons and surgery center administrators. Each week, Becker’s releases additions to their Ask Spine Surgeons series, and earlier this month, spine surgeons were asked to share their thoughts on the future of spine biologics. Check out Dr. Richard Kube’s response, below!
Question: Will the use of spine biologics continue to grow over the next decade?
Richard Kube, MD. Founder and CEO of Prairie Spine & Pain Institute (Peoria, Ill.): The short answer is yes. We have only just begun to understand much of the molecular biology of the structures of the spine. Certainly, multiple new treatments using stem cells, growth factors and potentially gene therapy, in the future, are on the horizon. Also, as we increase our understanding there are opportunities for better variety and hopefully more accurate diagnostic tools to improve patient selection. Careful study must be done with the utmost ethical practices as we strive to answer our questions.
This article originally posted on Beckersspine.com.
